Previous studies also showed that CYFIP2 was downregulated in ccRCC patients with an unfavorable survival outcome and might be a potential promising prognostic biomarker associated with immune infiltration, metabolism, and epithelial–mesenchymal transition process in ccRCC [31]. The gene discussed is CYFIP2; the disease is nonpapillary renal cell carcinoma.